VivoSim Labs 股价飙升,得益于强劲的业绩预期及礼来公司的里程碑付款

路透中文
Jul 15
BUZZ-VivoSim Labs 股价飙升,得益于强劲的业绩预期及<a href="https://laohu8.com/S/LLY">礼来</a>公司的里程碑付款

7月15日 - ** 生物技术公司VivoSim Labs(VIVS.O)的股价在盘前交易中上涨逾三倍,至2.81美元

** 受其药物安全性测试服务需求驱动,该公司预计2027财年营收将增长500%以上

** 该公司表示,在礼来公司(LLY.N)从VivoSim收购的炎症性肠病药物进入中期临床试验并完成首例患者给药后,已收到礼来支付的500万美元里程碑款项

** VivoSim可因该药物的开发和销售目标达成,获得最高4500万美元的额外里程碑付款

** VIVS表示,其实验室培育的人体组织模型有助于预测药物副作用,并减少对动物实验的依赖

** 该技术正吸引致力于基因疗法和抗体类药物研发的制药企业——VIVS

** 截至上一交易日收盘,VIVS股价年内累计下跌约54%

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10